On Monday, Shares of Twitter, Inc. (NYSE:TWTR), remained unchanged to $29.06.
Twitter Inc said on Tuesday it plans to accelerate its push for content partnerships in Asia Pacific and the Middle East, according to Reuters.
It has designated a Singapore-based executive, Rishi Jaitly, to boost teams in major markets such as Australia, India, and Japan in addition to expand into Greater China and Southeast Asia, the company said in a statement. Jaitly was formerly Twitter’s market director for India and Southeast Asia. Reuters Reports
Twitter has been aggressively expanding its capabilities to carry pictures, video and interactive content. Reuters added.
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
Shares of Chevron Corporation (NYSE:CVX), declined -1.99% to $83.23, during its last trading session, after oil fell about 1 percent on Monday, with U.S. crude settling within range of a new 6-1/2-year low, after No. 3 oil consumer Japan said its economy contracted in the second quarter and China’s slowdown continued to weigh on sentiment, according to Reuters.
U.S. light crude CLc1 settled down 63 cents, or 1.5 percent, at $41.87 a barrel. Monday’s intraday low of $41.64 came within striking distance of Friday’s low of $41.35, the weakest front-month price since March 2009. Trading in expiring options for U.S. crude dominated the action. Reuters Reports
Brent LCOc1, the global crude benchmark, settled down 45 cents, or nearly 1 percent, at $48.74 a barrel. It earlier hit a session low of $48.35, about $3 above its six-year low of $45.19 set in January. Reuters added.
Chevron Corporation, through its auxiliaries, engages in the petroleum, chemicals, and power and energy operations worldwide. The company operates in two segments, Upstream and Downstream.
Finally, Sorrento Therapeutics, Inc. (NASDAQ:SRNE), ended its last trade with 9.40% surge, and closed at $16.29.
Sorrento Therapeutics declared that it in addition to its wholly-owned partner TNK Therapeutics, Inc. have reached a binding term sheet to exclusively license the NanoVelcro Circulating Tumor Cell (CTC) profiling assay technology from CytoLumina Technologies Corp. and FetoLumina Technologies Corp., two privately-held sister biotechnology companies in Los Angeles, California. The exclusive licenses will cover the applications of the NanoVelcro CTC assay and its portfolio technologies for precision medicine diagnostics in conjunction with all cellular therapies and Sorrento antibody therapeutics.
The NanoVelcro Chip is a device capable of enriching, isolating, and identifying CTCs from peripheral blood of cancer patients. Coupled with downstream molecular assays, it enables the characterization of individually isolated CTCs, thus providing diagnostic information for the monitoring of real-time disease progression and tailoring individualized therapy solutions for cancer patients. The NanoVelcro Chip utilizes antibody-coated nanostructured substrates to capture CTCs with high efficiency. Once the CTCs are immobilized on the NanoVelcro Chips, laser capture microdissection technology allows for selective recovery of the CTCs with single-cell precision, virtually eliminating any trace of contamination from white blood cells that might complicate further downstream analysis. Finally, the isolated and purified CTCs are subjected to in-depth molecular characterization, counting mutational analysis, copy number variance, expression profiling, multi-color protein staining in addition to quantification of key phospho-proteins in signal transduction networks. These CTC-derived molecular signatures may assist doctors to implement personalized therapies targeting a patient’s unique cancer.
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
